Published in J Infect Dis on August 14, 2013
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nat Rev Microbiol (2017) 1.38
Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development. Sci Rep (2014) 1.36
Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging. Antimicrob Agents Chemother (2015) 1.09
Chagas disease and the london declaration on neglected tropical diseases. PLoS Negl Trop Dis (2014) 1.00
Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease. Antimicrob Agents Chemother (2015) 0.95
Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs. Antimicrob Agents Chemother (2015) 0.92
Population pharmacokinetics of benznidazole in adult patients with Chagas disease. Antimicrob Agents Chemother (2015) 0.92
VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis. J Infect Dis (2015) 0.89
Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity. Mem Inst Oswaldo Cruz (2014) 0.88
A new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in vivo imaging. J Biomol Screen (2014) 0.85
Translational challenges of animal models in Chagas disease drug development: a review. Drug Des Devel Ther (2015) 0.83
Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease. PLoS Pathog (2015) 0.83
Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade. PLoS Negl Trop Dis (2016) 0.83
Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives. Mem Inst Oswaldo Cruz (2015) 0.82
High throughput screening for anti-Trypanosoma cruzi drug discovery. PLoS Negl Trop Dis (2014) 0.79
New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients. Antimicrob Agents Chemother (2015) 0.79
Phenotypic Screening In Vitro of Novel Aromatic Amidines against Trypanosoma cruzi. Antimicrob Agents Chemother (2016) 0.78
A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease. Hum Vaccin Immunother (2016) 0.76
Nitro/nitrosyl-ruthenium complexes are potent and selective anti-Trypanosoma cruzi agents causing autophagy and necrotic parasite death. Antimicrob Agents Chemother (2014) 0.76
Reaching for the Holy Grail: insights from infection/cure models on the prospects for vaccines for Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz (2015) 0.76
The N-myristoylome of Trypanosoma cruzi. Sci Rep (2016) 0.75
Chronic Chagas' Disease: Targeting the Interleukin-2 Axis and Regulatory T Cells in a Condition for Which There Is No Treatment. Front Microbiol (2016) 0.75
Treatment Success in Trypanosoma cruzi Infection Is Predicted by Early Changes in Serially Monitored Parasite-Specific T and B Cell Responses. PLoS Negl Trop Dis (2016) 0.75
Success of benznidazole chemotherapy in chronic Trypanosoma cruzi-infected patients with a sustained negative PCR result. Eur J Clin Microbiol Infect Dis (2016) 0.75
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis (1998) 16.20
Control of neglected tropical diseases. N Engl J Med (2007) 14.49
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol (2004) 5.19
Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med (2006) 4.58
Control of Chagas disease. World Health Organ Tech Rep Ser (2002) 4.00
A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz (2002) 3.84
Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis (2007) 3.80
Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg (1987) 2.66
Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop (2009) 2.37
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med (2002) 2.36
Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo (2002) 2.20
Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J (1994) 2.14
Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med (2008) 2.04
Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther (2009) 1.99
Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem (2006) 1.98
CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog (2006) 1.93
Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. Mol Biochem Parasitol (2003) 1.88
In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Negl Trop Dis (2010) 1.72
Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis (2009) 1.62
Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol Biochem Parasitol (1998) 1.53
New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis (2012) 1.46
Present situation and new strategies for Chagas disease chemotherapy: a proposal. Mem Inst Oswaldo Cruz (2009) 1.33
Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem Inst Oswaldo Cruz (2011) 1.26
A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. J Antimicrob Chemother (2000) 1.23
HLA Class I-T cell epitopes from trans-sialidase proteins reveal functionally distinct subsets of CD8+ T cells in chronic Chagas disease. PLoS Negl Trop Dis (2008) 1.19
Multiple-dose kinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung (1980) 1.12
Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung (1979) 1.08
[Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation]. Rev Soc Bras Med Trop (1997) 1.06
Comparative studies of drug susceptibility of five strains of Trypanosoma cruzi in vivo and in vitro. Trans R Soc Trop Med Hyg (1988) 0.99
Trypanosoma cruzi: acute and long-term infection in the vertebrate host can modify the response to benznidazole. Exp Parasitol (2007) 0.99
Methodological advances in drug discovery for Chagas disease. Expert Opin Drug Discov (2011) 0.98
Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains. Int J Antimicrob Agents (2012) 0.95
Preclinical pharmacokinetics of benznidazole. Br J Cancer (1984) 0.93
Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev Inst Med Trop Sao Paulo (2000) 0.91
Report of the 2nd Chagas Drug Discovery Consortium meeting, held on 3 November 2010; Atlanta GA, USA. Expert Opin Drug Discov (2011) 0.90
Seronegative conversion after incomplete benznidazole treatment in chronic Chagas disease. Trans R Soc Trop Med Hyg (2012) 0.88
Trypanosoma cruzi: Induction of benznidazole resistance in vivo and its modulation by in vitro culturing and mice infection. Exp Parasitol (2008) 0.88
In vivo susceptibility to benznidazole of Trypanosoma cruzi strains from the western Brazilian Amazon. Trop Med Int Health (2012) 0.87
Boron-based drugs as antiprotozoals. Curr Opin Infect Dis (2011) 0.85
Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method. Antimicrob Agents Chemother (2012) 0.84
[Hemoculture in the LIT medium for Trypanosoma cruzi according to the Mourão-Mello method (1975)]. Rev Inst Med Trop Sao Paulo (1981) 0.77
A Heuristic method for assigning a false-discovery rate for protein identifications from Mascot database search results. Mol Cell Proteomics (2005) 2.52
Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med (2008) 2.04
CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog (2006) 1.93
Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. Mol Biochem Parasitol (2003) 1.88
Frequency of interferon- gamma -producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis (2004) 1.79
In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Negl Trop Dis (2010) 1.72
Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis (2009) 1.62
Trypanosoma cruzi modulates the profile of memory CD8+ T cells in chronic Chagas' disease patients. Int Immunol (2006) 1.51
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection. PLoS Negl Trop Dis (2008) 1.46
Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun (2002) 1.45
Chromosome level assembly of the hybrid Trypanosoma cruzi genome. BMC Genomics (2009) 1.42
Potential new clinical therapies for Chagas disease. Expert Rev Clin Pharmacol (2014) 1.42
CD8+ T cells in Trypanosoma cruzi infection. Curr Opin Immunol (2009) 1.36
The steady-state transcriptome of the four major life-cycle stages of Trypanosoma cruzi. BMC Genomics (2009) 1.33
Antigen-specific T cells maintain an effector memory phenotype during persistent Trypanosoma cruzi infection. J Immunol (2005) 1.33
HLA Class I-T cell epitopes from trans-sialidase proteins reveal functionally distinct subsets of CD8+ T cells in chronic Chagas disease. PLoS Negl Trop Dis (2008) 1.19
Insufficient TLR activation contributes to the slow development of CD8+ T cell responses in Trypanosoma cruzi infection. J Immunol (2009) 1.17
Cycling of the signaling protein phospholipase D through cilia requires the BBSome only for the export phase. J Cell Biol (2013) 1.16
Chronic human infection with Trypanosoma cruzi drives CD4+ T cells to immune senescence. J Immunol (2009) 1.12
Widespread, focal copy number variations (CNV) and whole chromosome aneuploidies in Trypanosoma cruzi strains revealed by array comparative genomic hybridization. BMC Genomics (2011) 1.09
Evaluation of high efficiency gene knockout strategies for Trypanosoma cruzi. BMC Microbiol (2009) 1.07
Eliminating Chagas disease: challenges and a roadmap. BMJ (2009) 1.06
Stable CD8+ T cell memory during persistent Trypanosoma cruzi infection. J Immunol (2008) 1.05
A systematic review of high quality diagnostic tests for Chagas disease. PLoS Negl Trop Dis (2012) 1.05
Cutting edge: dysfunctional CD8+ T cells reside in nonlymphoid tissues during chronic Trypanosoma cruzi infection. J Immunol (2003) 1.02
CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance. J Immunol (2010) 1.02
Methodological advances in drug discovery for Chagas disease. Expert Opin Drug Discov (2011) 0.98
Microarray profiling of gene expression during trypomastigote to amastigote transition in Trypanosoma cruzi. Mol Biochem Parasitol (2003) 0.98
Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection. Vaccine (2003) 0.96
Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease. PLoS One (2012) 0.95
Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge. Infect Immun (2011) 0.94
TGF-beta regulates pathology but not tissue CD8+ T cell dysfunction during experimental Trypanosoma cruzi infection. Eur J Immunol (2007) 0.91
A semi-quantitative GeLC-MS analysis of temporal proteome expression in the emerging nosocomial pathogen Ochrobactrum anthropi. Genome Biol (2007) 0.90
Report of the 2nd Chagas Drug Discovery Consortium meeting, held on 3 November 2010; Atlanta GA, USA. Expert Opin Drug Discov (2011) 0.90
Inducible nitric oxide synthase is not essential for control of Trypanosoma cruzi infection in mice. Infect Immun (2004) 0.89
Evidence for the role of vacuolar soluble pyrophosphatase and inorganic polyphosphate in Trypanosoma cruzi persistence. Mol Microbiol (2013) 0.89
Perpetual expression of PAMPs necessary for optimal immune control and clearance of a persistent pathogen. Nat Commun (2013) 0.88
TcruziDB: an integrated Trypanosoma cruzi genome resource. Nucleic Acids Res (2004) 0.88
Trypanosoma cruzi-specific immune responses in subjects from endemic areas of Chagas disease of Argentina. Microbes Infect (2010) 0.85
Generation of Trypanosoma cruzi-specific CD8+ T-cell immunity is unaffected by the absence of type I interferon signaling. Infect Immun (2010) 0.83
Multidimensional analysis of the insoluble sub-proteome of Oceanobacillus iheyensis HTE831, an alkaliphilic and halotolerant deep-sea bacterium isolated from the Iheya ridge. Proteomics (2007) 0.82
Transgenic parasites accelerate drug discovery. Trends Parasitol (2012) 0.80
Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge. PLoS Negl Trop Dis (2011) 0.80
Multidimensional proteomic analysis of the soluble subproteome of the emerging nosocomial pathogen Ochrobactrum anthropi. J Proteome Res (2006) 0.80
A combined shotgun and multidimensional proteomic analysis of the insoluble subproteome of the obligate thermophile, Geobacillus thermoleovorans T80. J Proteome Res (2006) 0.78
Trypanoside, anti-tuberculosis, leishmanicidal, and cytotoxic activities of tetrahydrobenzothienopyrimidines. Bioorg Med Chem (2010) 0.77